Connecticut will receive nearly $1.7 million as part of a $90 million, multi-state settlement with drug maker GlaxoSmithKline Plc over deceptive marketing practices, state Attorney General George Jepsen announced Nov. 15.
The settlement resolves allegations that the global pharmaceutical company engaged in deceptive marketing practices by misrepresenting the cardiovascular risks of its diabetes drug Avandia.
In addition to Connecticut, 37 other states participated in the settlement agreement.
The payout comes after Connecticut joined a $3 billion settlement between GSK and both the federal government and state governments over claims that the company engaged in illegal marketing practices relating to several drugs it manufactures, including Paxil, Wellbutrin and Avandia.
